Abstract:Dementia exists as a 'progressive clinical syndrome of deteriorating mental function significant enough to interfere with activities of daily living', with the most prevalent type of dementia being Alzheimer's disease (AD), accounting for about 80% of diagnosed cases. AD is associated with an increased risk of comorbidity with other clinical conditions such as hypertension, diabetes, and neuropsychiatric symptoms (NPS) including, agitation, anxiety, and depression as well as increased mortality in late life. For example, up to 70% of patients diagnosed with AD are affected by anxiety. As aging is the major risk factor for AD, this represents a huge global burden in ageing populations. Over the last 10 years, significant efforts have been made to recognize the complexity of AD and understand the aetiology and pathophysiology of the disease as well as biomarkers for early detection. Yet, earlier treatment options, including acetylcholinesterase inhibitors and glutamate receptor regulators, have been limited as they work by targeting the symptoms, with only the more recent FDA-approved drugs being designed to target amyloid-β protein with the aim of slowing down the progression of the disease. However, these drugs may only help temporarily, cannot stop or reverse the disease, and do not act by reducing NPS associated with AD. The first-line treatment options for the management of NPS are selective serotonin reuptake inhibitors/selective noradrenaline reuptake inhibitors (SSRIs/SNRIs) targeting the monoaminergic system; however, they are not rational drug choices for the management of anxiety disorders since the GABAergic system has a prominent role in their development. Considering the overall treatment failures and side effects of currently available medication, there is an unmet clinical need for rationally designed therapies for anxiety disorders associated with AD. In this review, we summarize the current status of the therapy of AD and aim to highlight novel angles for future drug therapy in our ongoing efforts to alleviate the cognitive deficits and NPS associated with this devastating disease.

Monoamine alterations in Alzheimer's disease and their implications in comorbid neuropsychiatric symptoms

Behavioral and Psychological Symptoms in Alzheimer's Disease.

Neurometabolic Characteristics in the Anterior Cingulate Gyrus of Alzheimer’s Disease Patients with Depression: a 1H Magnetic Resonance Spectroscopy Study

Prevalence of Neuropsychiatric Symptoms Across the Declining Memory Continuum: an Observational Study in a Memory Clinic Setting

Neuropsychiatric symptoms associated multimodal brain networks in Alzheimer's disease

Advances in Therapeutics to Alleviate Cognitive Decline and Neuropsychiatric Symptoms of Alzheimer's Disease

P3-459: Neuropsychiatric Features in Alzheimer's Disease and Mild Cognitive Impairment in Memory Clinic

The neural basis of neuropsychiatric symptoms in Alzheimer's disease

The Prevalence Of Neuropsychiatric Symptoms In Alzheimer'S Disease: Systematic Review And Meta-Analysis (Vol 190, Pg 264, 2016)

Depression In Alzheimer'S Disease: Epidemiology, Mechanisms, And Management

Depression in Alzheimer's Disease: Epidemiology, Mechanisms, and Management.

Characteristics of neuropsychiatric symptoms among individuals with Alzheimer's disease in a memory clinic setting

The neurotransmitter puzzle of Alzheimer's: Dissecting mechanisms and exploring therapeutic horizons

Alzheimer´s Disease in the Perspective of Neuroimmunology

Pathogenesis of Depression in Alzheimer's Disease

Depression in Alzheimer's disease: epidemiology, mechanisms, and treatment

Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer's disease

Amygdala neuronal dyshomeostasis via 5‐HT receptors mediates mood and cognitive defects in Alzheimer's disease

Interactions between mild depressive symptoms and amyloid pathology on the trajectory of neurodegeneration, cognitive decline, and risk of Alzheimer's disease

An overview of the pathophysiology of agitation in Alzheimer's dementia with a focus on neurotransmitters and circuits

Emotional and Neuropsychiatric Disorders Associated with Alzheimer’s Disease